Tactile Medical 10-Q: Q3 Revenue $91.9M, New COO Named, $75.1M Cash
TCMD sits 54% above its 52-week low of $14.84.
Summary
Tactile's Q3 10-Q confirms $91.9M revenue (+7%) and $0.31 diluted EPS, adds a new COO and an executive departure, and shows cash down to $75.1M after $12.5M of buybacks.
Key Events · Earnings and Guidance · TCMD
-
Q3 Revenue Grows 7% to $91.9M
Lymphedema sales and rentals rose 13% to $81.8M, offsetting a 25% decline in airway clearance to $10.0M tied to the AffloVest DME inventory transition.
-
Margins Expand, Net Income Slips
Gross margin rose to 77% from 76%, but operating expenses grew 13% to $60.9M and net income fell to $7.2M ($0.31 diluted) from $8.2M ($0.36).
-
New COO Appointed
Stephen A. Kiewiet became Chief Operating Officer on November 2, 2026, with a $385,000 base salary, $350,000 sign-on equity split between RSUs and PSUs, and a 45% target bonus.
-
SVP Business Development Role Eliminated
Kristie Burns was notified October 27, 2026 that her position ends November 2, 2026; she stays as an employee through December 31, 2026 with severance and a waived 2026 MIP employment condition.
Analysis · TCMD · Industrial Applications And Services
The 10-Q confirms the Q3 numbers already released this morning — revenue up 7% to $91.9M, net income down to $7.2M ($0.31 diluted) from $8.2M — but adds two items the 8-K did not carry: a new Chief Operating Officer (Stephen Kiewiet, $385,000 salary plus $350,000 sign-on equity) and the elimination of the SVP Business Development role. The balance sheet is the real story: cash fell to $75.1M from $83.4M at year-end after $12.5M of buybacks at a $24.92 average, and $2.2M of LymphaTech earnout becomes payable by November 12. The False Claims Act suits are now settled and dismissed, leaving only a $0.2M fee dispute.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TCMD was trading at $22.87 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $518.1M. The 52-week trading range was $14.84 to $37.77. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.